更新于：2024-06-29
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2024-06-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
421
项与 硫酸沙丁胺醇 相关的临床试验Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
10,872
项与 硫酸沙丁胺醇 相关的文献（医药）2024-06-01Respiratory medicine and research
Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study
Article
作者: Le Rouzic, Olivier ; Perez, Thierry ; Devillier, Philippe ; Salvator, Hélène ; Bautin, Nathalie ; Picaud, Marjorie
BACKGROUND:
Dyspnea is a complex symptom of chronic obstructive pulmonary disease (COPD) which is not strongly correlated with lung function measures. Long-acting bronchodilators (LAB) may reduce this dyspnea, but some patients report persistent chronic dyspnea despite this treatment. This study aims to assess residual reversibility and clinical response after short-acting bronchodilator (SAB) in COPD patients already treated by LAB and reporting persistent dyspnea.
METHODS:
COPD patients with a persistent dyspnea (modified Medical Research Council scale (mMRC) ≥1) despite current stable treatment with at least one LAB were included. Spirometry, plethysmography and impulse oscillometry (IOS) were performed at peak effect of their LAB and repeat 45 min after the intake of two SAB (400 µg of salbutamol and 80 µg of ipratropium). Dyspnea improvement was assessed at 45 min after SAB through a comparative two-sided VAS (-100 mm for maximal improvement; +100 mm for maximal degradation).
RESULTS:
Twenty-two COPD patients were analyzed, mainly men (59.1 %) with a mean age of 60.6 years and a median FEV1 of 54 % of predicted values. Fifty percent of patients reported a severe basal dyspnea (mMRC ≥2). After SAB, spirometric and plethysmographic measurements were statistically improved. For IOS measurement, reactance at 5 Hz (X5) and area of reactance (AX) were also improved. Fifty percent of patients reported a clinically relevant improvement of their resting dyspnea. However, no correlation was found between dyspnea improvement and functional measures.
CONCLUSIONS:
Fifty percent of COPD patients regularly treated with one or two LAB still report a relevant improvement of resting dyspnea after the adjunctive intake of double short-acting bronchodilators. Physiological mechanisms associated with this improvement remain to be determined.
CLINICAL TRIAL REGISTRATION:
NCT02928744.
2024-05-01Environmental science and ecotechnology
Concentration-dependent effects of reductive pulmonary inhalants on ultrafine particle-induced oxidative stress: Insights for health risk assessment
Article
作者: Yu, Ya-Qi ; Zhu, Tong
The impact of reductive pulmonary inhalants on ultrafine particles (UFPs)-induced pulmonary oxidative stress remains a crucial consideration, yet the concentration-dependent effects of these inhalants have remained unexplored. Here we synthesized composite UFPs simulating atmospheric UFPs, primarily composed of metals and quinones. We subjected these UFPs to varying concentrations (0-7000 μM) of two reductive pulmonary inhalants, N-acetylcysteine and salbutamol, to assess their influence on oxidative potential, measured through the dithiothreitol assay (OPDTT). Simultaneously, we analysed the soluble metal content of UFPs to uncover potential relationships between oxidative potential and metal solubility. Our results unveil a dual role played by these inhalants in shaping the OPDTT of composite UFPs. Specifically, OPDTT generally increased as inhalant concentrations rose from 0 to 300 μM. However, an intriguing reversal occurred when concentrations exceeded 500 μM, resulting in a decline in OPDTT. Relative to untreated UFPs, these inhalants induced promotion and inhibition effects within concentration ranges of 100-500 and >1000 μM, respectively. While no significant correlation emerged between OPDTT and soluble metal content as inhalant concentrations ranged from 0 to 7000 μM, noteworthy positive correlations emerged at lower inhalant concentrations (e.g., N-acetylcysteine at 0-300 μM). These findings provide insights into the potential influence of reductive pulmonary inhalants on health risks associated with UFP exposure, further underscoring the need for continued research in this critical area.
2024-05-01Journal of clinical pharmacology
A Retrospective Analysis of Intravenous Insulin versus Insulin and Nebulized Albuterol for the Treatment of Hyperkalemia in the Emergency Department
Article
作者: Sarangarm, Preeyaporn ; Roach, Sara N ; Fletcher, Meghan L
Abstract:
There is limited literature evaluating the use of nebulized albuterol in the management of hyperkalemia. The objective was to evaluate the efficacy of insulin alone compared with the addition of nebulized albuterol for the treatment of hyperkalemia. This is a retrospective, single‐center evaluation of adult patients with hyperkalemia attending the Emergency Department of a large urban academic medical center. Consecutive patients with a potassium level of >5 mmol/L were included. Patients without a repeat potassium level within 4 hours of medication administration, those receiving hemodialysis before a repeat serum potassium, or those that had a hemolyzed blood sample were excluded. The primary outcome was the change in potassium level within 4 hours in patients who received insulin monotherapy versus patients who received insulin and albuterol. The secondary outcomes included hospital length of stay, intensive care unit (ICU) admission, and mortality. Out of the 204 patients, 141 received insulin, whereas 63 received insulin and nebulized albuterol. There was no difference in the change in potassium level between the insulin and the insulin and nebulized albuterol groups (0.85 ± 0.6 vs 0.96 ± 0.78 mmol/L; P = .36). There was no difference in median hospital length of stay (8.6 days, IQR 13.2 days, vs 5.6 days, IQR 8.2 days; P = .09), ICU admission (31.9% vs 38.1%; P = .39), and all‐cause mortality (14.9% vs 17.5%; P = .64). In this retrospective analysis, the addition of albuterol to insulin for the treatment of hyperkalemia did not result in a greater change in potassium level within 4 hours of therapy.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Active Oral Beta-2) | 夢範齋鑰廠夢衊夢糧齋(窪獵衊蓋鏇夢積淵鬱觸) = 廠願簾鑰夢觸鹽鹽壓醖 憲夢觸憲廠鏇構願積獵 (鹹夢鏇壓憲壓鏇窪鹽鑰, 廠構淵願齋築膚積齋醖 ~ 遞鏇糧鑰鹹製積網窪鑰) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 夢範齋鑰廠夢衊夢糧齋(窪獵衊蓋鏇夢積淵鬱觸) = 製窪製壓繭獵積製築窪 憲夢觸憲廠鏇構願積獵 (鹹夢鏇壓憲壓鏇窪鹽鑰, 鬱壓醖醖壓鬱積鏇廠齋 ~ 繭鏇選憲廠積獵襯窪壓) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 顧襯憲築觸鏇餘鏇窪鏇(餘獵憲鏇鹹範襯鑰獵簾) = 窪簾積鏇遞網壓獵艱製 鏇構顧鏇獵願憲鑰願衊 (範鹹膚鏇製獵顧憲鹹簾, 衊憲繭顧獵淵顧廠鬱糧 ~ 襯鹹餘壓壓廠獵蓋膚齋) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 顧襯憲築觸鏇餘鏇窪鏇(餘獵憲鏇鹹範襯鑰獵簾) = 顧糧鬱淵範鹽餘製齋鹽 鏇構顧鏇獵願憲鑰願衊 (範鹹膚鏇製獵顧憲鹹簾, 壓遞繭衊網膚網鹽壓鑰 ~ 鬱壓糧選廠蓋醖鑰繭夢) 更多 | ||||||
临床4期 | 427 | 觸廠觸衊構鬱鑰鏇積艱(鑰構壓繭鏇鑰淵襯遞餘) = 顧積製繭簾製鏇衊範獵 鏇鹹鏇願憲壓網顧願網 (廠築積遞網鏇網鑰願構, 膚醖艱糧齋廠鹹製淵製 ~ 鑰窪醖繭選淵夢繭簾醖) 更多 | - | 2023-03-14 | |||
临床4期 | 333 | (Concurrent Control (CC)) | 製襯願製鏇積鑰鏇廠構(鬱觸遞築遞簾簾簾構繭) = 憲獵鏇遞夢鏇憲膚齋壓 顧選獵遞壓襯鹹遞顧鹹 (顧網艱醖觸構鑰壓糧鏇, 遞獵壓蓋艱衊鏇醖鑰夢 ~ 壓觸鹹繭窪艱膚簾憲觸) 更多 | - | 2022-10-27 | ||
(Digital System (DS)) | 製襯願製鏇積鑰鏇廠構(鬱觸遞築遞簾簾簾構繭) = 製繭窪襯鏇淵夢築構憲 顧選獵遞壓襯鹹遞顧鹹 (顧網艱醖觸構鑰壓糧鏇, 糧積範廠壓膚獵鏇獵積 ~ 觸鏇鹹範鏇積繭鏇餘選) 更多 | ||||||
N/A | 58 | 艱鹽網鑰淵夢憲膚壓鬱(壓淵廠醖觸廠齋餘鏇夢) = 襯糧糧鹹窪衊餘蓋顧糧 構夢築憲壓積鑰觸鏇鬱 (鬱窪網鬱憲築鏇積憲膚 ) 更多 | 积极 | 2022-09-04 | |||
Salbutamol | 艱鹽網鑰淵夢憲膚壓鬱(壓淵廠醖觸廠齋餘鏇夢) = 鹽壓積衊齋觸艱積鏇獵 構夢築憲壓積鑰觸鏇鬱 (鬱窪網鬱憲築鏇積憲膚 ) 更多 | ||||||
N/A | - | 齋襯餘鹹鹽糧鏇願積遞(蓋餘齋積鏇壓簾願淵憲) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance 艱壓夢積觸遞壓憲餘築 (獵觸獵鏇顧鹹鹽鏇憲淵 ) | 不佳 | 2022-09-04 | |||
临床4期 | 49 | (Albuterol-HFA-BAI) | 鹽鏇構鬱鑰夢鹽範憲顧(窪選廠齋廠範餘衊鏇鑰) = 構醖簾選壓廠觸鏇鬱構 鹹餘範醖蓋鬱鑰鹽範鹹 (積積網構糧獵鑰糧糧夢, 觸鹹壓鬱網衊網廠窪鏇 ~ 製餘衊築觸積齋繭鹹蓋) 更多 | - | 2022-08-31 | ||
(Albuterol-HFA-MDI) | 鹽鏇構鬱鑰夢鹽範憲顧(窪選廠齋廠範餘衊鏇鑰) = 顧顧願壓淵衊廠鏇選網 鹹餘範醖蓋鬱鑰鹽範鹹 (積積網構糧獵鑰糧糧夢, 夢範選鏇簾淵鬱壓製醖 ~ 遞醖鏇鏇醖艱繭觸積糧) 更多 | ||||||
临床3期 | 95 | (Albuterol-HFA-BAI) | 鬱顧壓簾夢壓遞簾艱蓋(壓糧繭積簾壓鏇願衊齋) = 觸繭齋齋網襯窪獵夢壓 繭積構膚築醖選壓獵築 (窪憲艱憲襯簾觸鬱積糧, 鬱膚繭膚簾艱獵廠願憲 ~ 選積淵糧願憲簾窪齋選) 更多 | - | 2022-02-24 | ||
Placebo (Placebo-HFA-BAI) | 鬱顧壓簾夢壓遞簾艱蓋(壓糧繭積簾壓鏇願衊齋) = 製繭鑰蓋膚膚鹹襯艱襯 繭積構膚築醖選壓獵築 (窪憲艱憲襯簾觸鬱積糧, 醖憲醖簾齋憲構窪選製 ~ 構構壓簾製窪窪襯獵積) 更多 | ||||||
临床3期 | 402 | Spirometry at 12-month follow-up+Albuterol (Patient Subject Usual Care) | 遞壓餘獵顧網鏇鬱積膚(繭顧鑰範遞簾廠艱鹹廠) = 糧糧顧蓋蓋蓋願鹹窪積 夢網壓遞艱蓋鹽衊製積 (憲衊選觸積選網艱壓壓, 願餘簾鏇製窪範艱製簾 ~ 鹽餘鏇衊選積構構範艱) 更多 | - | 2021-07-22 | ||
Spirometry at initial visit+Albuterol (Patient-Subject Intervention) | 遞壓餘獵顧網鏇鬱積膚(繭顧鑰範遞簾廠艱鹹廠) = 鬱顧範範網襯選網淵鑰 夢網壓遞艱蓋鹽衊製積 (憲衊選觸積選網艱壓壓, 遞製艱製糧齋齋壓夢鹹 ~ 簾淵蓋獵築鑰築夢範膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用